Evidence map›Paper›PMID 30037325›Full record

ArticleBMC infectious diseases2018

Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) among travellers to Africa: destination-specific data pooled from three European prospective studies.

Tinja Lääveri, Jessica A Vlot, Alje P van Dam, Hanni K Häkkinen, Gerard J B Sonder, Leo G Visser, Anu Kantele

Abstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Vacation in Egypt associated with Shiga toxin-producingEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Antimicrobial Resistance inFrontiers in medicine · 2021
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tinja LääveriInflammation Center, Division of Infectious Diseases, University of Helsinki and Helsinki University Hospital, POB 348, FIN-00029 HUS,, Helsinki, Finland.
Jessica A VlotDepartment of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Alje P van DamDepartment of Infectious Diseases, Public Health Service (GGD), Amsterdam, The Netherlands.
Hanni K HäkkinenClinicum, University of Helsinki, Helsinki, Finland.
Gerard J B SonderDepartment of Infectious Diseases, Public Health Service (GGD), Amsterdam, The Netherlands.
Leo G VisserDepartment of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Anu KanteleInflammation Center, Division of Infectious Diseases, University of Helsinki and Helsinki University Hospital, POB 348, FIN-00029 HUS,, Helsinki, Finland. anu.kantele@hus.fi.ORCID 0000-0002-0004-1000

Funding

Finnish government subsidy for health science research TYH2012141, TYH 2013218 and TYH 2014216SSAC foundation SLS-504141ZonMw, the Netherlands Organisation for Health Research and Development 125020011
6 · The paper itself

Abstract

backgroundOne third of travellers to low- and middle-income regions of the tropics and subtropics become colonized by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE). The risk varies by destination and, for each traveller, may be substantially further increased by travellers' diarrhoea (TD) and antibiotic use. Despite the risk of TD in Africa, ESBL-PE acquisition rates in all studies are lower there than in Asia. Africa has become increasingly popular as a destination for international travellers, yet minimal data are available from the continent's subregions and countries.

methodsWe analysed subregion- and country-specific data on carriage and risk factors for ESBL-PE colonization pooled from three prospective studies conducted between 2009 and 2013 among Finnish and Dutch travellers. The data were subjected to multivariable analysis of risk factors. In addition, we compared our data to two recent large investigations reporting data by subregion and country.

resultsOur joint analysis comprised data on 396 travellers. The ESBL-PE colonization rate was highest in Northern Africa, followed by Middle and Eastern Africa, and lowest in Southern and Western Africa. Of individual countries with more than 15 visitors, the highest rates were seen for Egypt (12/17; 70.6%), Ghana (6/23; 26.1%), and Tanzania (14/81; 17.3%); the rates among travellers to Egypt were comparable to those reported in South and Southeast Asia. In a pooled multivariable analysis, travel destination, age, overnight hospitalisation abroad, TD, and use of fluoroquinolones were independently associated with increased ESBL-PE colonization rates. CONLUSIONS: Even in areas with relatively low risk of colonization, antimicrobials clearly predispose to colonization with ESBL-PE. Travellers to Africa should be cautioned against unnecessary use of antibiotics.

Indexed as

Drug Resistance, BacterialEnterobacteriaceae InfectionsTravelAfricaAnti-Bacterial AgentsEnterobacteriaceaeEuropeHumansProspective StudiesRetrospective StudiesRisk FactorsAnti-Bacterial AgentsAfricaAntimicrobialsEnterobacteriaceaeESBLExtended-spectrum beta-lactamaseMDRTravel

Identifiers

PMID30037325
PMCPMC6057027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.